Advertisement
Singapore markets open in 3 hours 59 minutes
  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • Dow

    38,503.69
    +263.71 (+0.69%)
     
  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     
  • Bitcoin USD

    66,269.59
    -240.55 (-0.36%)
     
  • CMC Crypto 200

    1,427.43
    +12.67 (+0.90%)
     
  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     
  • Gold

    2,336.40
    -10.00 (-0.43%)
     
  • Crude Oil

    83.36
    +1.46 (+1.78%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     
  • Jakarta Composite Index

    7,110.81
    -7,073.82 (-49.87%)
     
  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

What Analysts Recommend for Merck and AstraZeneca in June

What Analysts Recommend for Merck and AstraZeneca in June

Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.